Advertisement
Advertisement

CTMX

CTMX logo

CytomX Therapeutics, Inc.

3.79
USD
Sponsored
-0.09
-2.32%
May 13, 16:00 UTC -4
Closed
exchange

Pre-Market

3.77

-0.02
-0.40%

CytomX Therapeutics, Inc. Profile

About

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.

Info & Links

CEO

Sean A. McCarthy

Headquarters

151 OYSTER POINT BLVD.SUITE 400
SOUTH SAN FRANCISCO, CA 94080, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.cytomx.com

Auditor

Ernst & Young LLP

Share holders

16

Employees

69

CytomX Therapeutics, Inc. Statistics

Valuation Measures

Market Capitalization2

821.83M

Enterprise Value

809.16M

Enterprise Value/EBITDA(ttm)

-34.89

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

9.47

Price to Book(mrq)

7.26

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-22.79%

Profit Margin(ttm)

-1161.13%

Return on Equity(ttm)

-19.77%

Return on Invested Capital(ttm)

53.76%

Return on Assets(ttm)

-11.91%

Income Statement

Revenue(ttm)

76.20M

Revenue Per Share(ttm)

0.45

Gross Profit(ttm)

76.20M

EBITDA(ttm)3

-23.19M

Net Income Available to Common(ttm)

-20.37M

Diluted EPS(ttm)

-0.04

Share Statistics

Beta (5Y Monthly)

2.49

52-Week Change

51.60%

S&P 500 52-Week Change

26.33%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

170.19M

Dividend Yield

0.00%

Float4

158.96M

% Held by Insiders

6.60%

% Held by Institutions

67.77%

Balance Sheet

Total Cash(mrq)

137.05M

Total Cash Per Share(mrq)

0.81

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

3.09%

Quick Ratio(mrq)

3.09%

Book Value Per Share(mrq)

0.58

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.55

Free Cash Flow(ytd)

-75.81M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement